CCDC62
gene geneOn this page
Also known as TSP-NYFLJ40344CT109ERAP75
Summary
CCDC62 (coiled-coil domain containing 62, HGNC:30723) is a protein-coding gene on chromosome 12q24.31, encoding Coiled-coil domain-containing protein 62 (Q6P9F0). Nuclear receptor coactivator that can enhance preferentially estrogen receptors ESR1 and ESR2 transactivation.
Enables nuclear estrogen receptor binding activity and transcription coactivator activity. Involved in several processes, including cellular response to estradiol stimulus; estrogen receptor signaling pathway; and positive regulation of transcription by RNA polymerase II. Located in acrosomal vesicle and nucleus. Implicated in spermatogenic failure 67.
Source: NCBI Gene 84660 — RefSeq curated summary.
At a glance
- GWAS associations: 27
- Clinical variants (ClinVar): 116 total — 1 pathogenic
- Phenotypes (HPO): 4
- MANE Select transcript:
NM_201435
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:30723 |
| Approved symbol | CCDC62 |
| Name | coiled-coil domain containing 62 |
| Location | 12q24.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | TSP-NY, FLJ40344, CT109, ERAP75 |
| Ensembl gene | ENSG00000130783 |
| Ensembl biotype | protein_coding |
| OMIM | 613481 |
| Entrez | 84660 |
Gene structure
Transcript identifiers
Ensembl transcripts: 5 — 4 protein_coding, 1 nonsense_mediated_decay
ENST00000253079, ENST00000341952, ENST00000392441, ENST00000537566, ENST00000539171
RefSeq mRNA: 1 — MANE Select: NM_201435
NM_201435
CCDS: CCDS9238
Canonical transcript exons
ENST00000253079 — 13 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000895263 | 122792020 | 122792121 |
| ENSE00000895264 | 122797307 | 122797395 |
| ENSE00000895281 | 122801124 | 122801852 |
| ENSE00000895283 | 122806151 | 122806295 |
| ENSE00001120905 | 122798085 | 122798200 |
| ENSE00001250716 | 122813270 | 122813419 |
| ENSE00001326557 | 122788758 | 122788929 |
| ENSE00001334482 | 122785719 | 122785820 |
| ENSE00001334485 | 122781164 | 122781330 |
| ENSE00001334486 | 122777491 | 122777683 |
| ENSE00001378819 | 122823366 | 122823459 |
| ENSE00002207123 | 122826422 | 122827528 |
| ENSE00002218471 | 122774572 | 122774706 |
Expression profiles
Bgee: expression breadth ubiquitous, 157 present calls, max score 97.35.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0961 / max 75.2682, expressed in 5 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 128532 | 0.0409 | 4 |
| 128530 | 0.0382 | 3 |
| 128528 | 0.0081 | 4 |
| 128529 | 0.0046 | 3 |
| 128531 | 0.0043 | 2 |
Top tissues by expression
239 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sperm | CL:0000019 | 97.35 | gold quality |
| left testis | UBERON:0004533 | 90.27 | gold quality |
| right testis | UBERON:0004534 | 89.35 | gold quality |
| adult organism | UBERON:0007023 | 88.47 | gold quality |
| testis | UBERON:0000473 | 87.62 | gold quality |
| tibialis anterior | UBERON:0001385 | 80.06 | silver quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 75.82 | gold quality |
| ileal mucosa | UBERON:0000331 | 68.18 | gold quality |
| upper leg skin | UBERON:0004262 | 66.08 | gold quality |
| skin of hip | UBERON:0001554 | 64.46 | gold quality |
| calcaneal tendon | UBERON:0003701 | 62.65 | gold quality |
| cortical plate | UBERON:0005343 | 62.49 | gold quality |
| amniotic fluid | UBERON:0000173 | 62.44 | gold quality |
| gastrocnemius | UBERON:0001388 | 62.40 | gold quality |
| pancreatic ductal cell | CL:0002079 | 62.39 | silver quality |
| muscle of leg | UBERON:0001383 | 62.32 | gold quality |
| deltoid | UBERON:0001476 | 62.03 | silver quality |
| oral cavity | UBERON:0000167 | 61.43 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 59.84 | gold quality |
| prefrontal cortex | UBERON:0000451 | 58.53 | gold quality |
| stromal cell of endometrium | CL:0002255 | 58.06 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 57.86 | gold quality |
| cerebellar vermis | UBERON:0004720 | 57.74 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 57.71 | gold quality |
| primary visual cortex | UBERON:0002436 | 57.68 | gold quality |
| corpus callosum | UBERON:0002336 | 57.34 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 57.27 | gold quality |
| cerebellar cortex | UBERON:0002129 | 57.23 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 57.15 | gold quality |
| leukocyte | CL:0000738 | 56.41 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.50 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
1 targets.
| Target | Regulation |
|---|---|
| CXCL12 | Activation |
Upstream regulators (CollecTRI, top): ESR2
Literature-anchored findings (GeneRIF, showing 8)
- ERAP75 functions as a novel coactivator that can modulate ER alpha function in the prostate stromal cells. (PMID:18563714)
- Role of CCDC62/ERAP75 as a novel coactivator in prostate cancer cells that can modulate estrogen receptor beta transactivation and receptor function. (PMID:19126643)
- serological survey of 191 cancer patients with a range of different cancers by ELISA revealed antibodies to CCDC62-2 in 13 patients, including stomach cancer (PMID:19165854)
- STK39 (rs2102808) and CCDC62/HIP1R (rs12817488) do not appear to influence PD risk. (PMID:24312176)
- Study demonstrated a significant association between rs12817488 and sporadic Parkinson’s disease with gender variations in a Chinese cohort (PMID:24335092)
- our findings support the conclusion that the rs12817488 in CCDC62/HIP1R polymorphism may increase the risk of Parkinson’s disease in the Chinese Han population. (PMID:25818163)
- there is a relationship between rs12817488 and Parkinson’s disease risk in Chinese population [meta-analysis] (PMID:27035708)
- This study shown CCDC62 genetic variants for Parkinson’s disease are associated with the risk of incident Parkinson’s disease in the general population and with impairment in daily functioning in individuals without clinical parkinsonism. (PMID:27269966)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Ccdc62 | ENSMUSG00000061882 |
| rattus_norvegicus | Ccdc62 | ENSRNOG00000038002 |
Protein
Protein identifiers
Coiled-coil domain-containing protein 62 — Q6P9F0 (reviewed: Q6P9F0)
Alternative names: Protein TSP-NY, Protein aaa
All UniProt accessions (2): Q6P9F0, F5H0F1
UniProt curated annotations — full annotation on UniProt →
Function. Nuclear receptor coactivator that can enhance preferentially estrogen receptors ESR1 and ESR2 transactivation. Also modulates progesterone/PGR, glucocorticoid/NR3C1 and androgen/AR receptors transactivation, although at lower level; little effect on vitamin D receptor/VDR. Required for normal spermiogenesis. It probably plays a role in acrosome formation.
Subunit / interactions. Interacts with ESR1 and ESR2 in the presence of estradiol/E2. The interaction with ESR2 recruits CCDC62 to ER target genes, including cyclin-D1/CCND1 AP-1 promoter. Interacts with GOPC.
Subcellular location. Cytoplasm. Nucleus. Cytoplasmic vesicle. Secretory vesicle. Acrosome.
Tissue specificity. Highly expressed in adult testis. Expressed in both prostate epithelial and stromal cells, with predominant expression in epithelial cells (at protein level). Not detected in prostate by RT-PCR. Overexpressed in various cancers.
Disease relevance. Spermatogenic failure 67 (SPGF67) [MIM:619803] An autosomal recessive male infertility disorder characterized by globozoospermia. Affected individuals have a normal sperm count, but spermatozoa are round-headed and lack the acrosome. In addition to pure globozoospermia, some patients have a mixture of acrosomeless spermatozoa and spermatozoa with small or detached acrosomes, which is defined as acrosomal hypoplasia. The disease may be caused by variants affecting the gene represented in this entry.
Domain organisation. Contains 2 Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. The first one is essential for the association with ESR1 and ESR2.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6P9F0-1 | 1 | yes |
| Q6P9F0-2 | 2 | |
| Q6P9F0-3 | 3 |
RefSeq proteins (1): NP_958843* (*=MANE)
Domains & families (InterPro)
UniProt features (21 total): sequence variant 5, splice variant 3, region of interest 2, mutagenesis site 2, sequence conflict 2, coiled-coil region 2, short sequence motif 2, compositionally biased region 2, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6P9F0-F1 | 65.07 | 0.38 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Mutagenesis-validated functional residues (2):
| Position | Phenotype |
|---|---|
| 637–638 | abrogates interaction with esr1 and esr2. |
| 653–654 | no effect on interaction with esr1 or esr2. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 110 (showing top):
GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_RESPONSE_TO_ESTRADIOL, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOCC_SECRETORY_GRANULE, GOBP_MALE_GAMETE_GENERATION, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, GOBP_BLASTOCYST_DEVELOPMENT, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_RESPONSE_TO_STEROID_HORMONE, GOBP_RESPONSE_TO_HORMONE
GO Biological Process (5): blastocyst hatching (GO:0001835), spermatid development (GO:0007286), estrogen receptor signaling pathway (GO:0030520), positive regulation of transcription by RNA polymerase II (GO:0045944), cellular response to estradiol stimulus (GO:0071392)
GO Molecular Function (3): transcription coactivator activity (GO:0003713), nuclear estrogen receptor binding (GO:0030331), protein binding (GO:0005515)
GO Cellular Component (5): acrosomal vesicle (GO:0001669), nucleus (GO:0005634), microtubule organizing center (GO:0005815), cytoplasm (GO:0005737), cytoplasmic vesicle (GO:0031410)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| positive regulation of DNA-templated transcription | 2 |
| cellular anatomical structure | 2 |
| blastocyst development | 1 |
| hatching | 1 |
| germ cell development | 1 |
| spermatid differentiation | 1 |
| nuclear receptor-mediated steroid hormone signaling pathway | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| transcription by RNA polymerase II | 1 |
| response to estradiol | 1 |
| cellular response to lipid | 1 |
| cellular response to oxygen-containing compound | 1 |
| transcription coregulator activity | 1 |
| nuclear receptor binding | 1 |
| binding | 1 |
| secretory granule | 1 |
| intracellular membrane-bounded organelle | 1 |
| microtubule cytoskeleton | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
| intracellular vesicle | 1 |
Protein interactions and networks
STRING
542 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CCDC62 | ACMSD | Q8TDX5 | 777 |
| CCDC62 | MCCC1 | Q96RQ3 | 774 |
| CCDC62 | HIP1R | O75146 | 736 |
| CCDC62 | SYT11 | Q9BT88 | 721 |
| CCDC62 | SYT12 | Q8IV01 | 720 |
| CCDC62 | GAK | O14976 | 700 |
| CCDC62 | STK39 | Q9UEW8 | 693 |
| CCDC62 | SPACA1 | Q9HBV2 | 624 |
| CCDC62 | STBD1 | O95210 | 616 |
| CCDC62 | DGKQ | P52824 | 602 |
| CCDC62 | ESR2 | Q92731 | 601 |
| CCDC62 | RIT2 | Q99578 | 596 |
| CCDC62 | DPY19L2 | Q6NUT2 | 595 |
| CCDC62 | SPATA16 | Q9BXB7 | 581 |
| CCDC62 | FAM47E | Q6ZV65 | 580 |
IntAct
17 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CFTR | ESYT2 | psi-mi:“MI:0914”(association) | 0.710 |
| CCDC62 | ESR2 | psi-mi:“MI:0915”(physical association) | 0.600 |
| ESR2 | CCDC62 | psi-mi:“MI:0407”(direct interaction) | 0.600 |
| ESR2 | CCDC62 | psi-mi:“MI:0915”(physical association) | 0.600 |
| CFTR | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.480 |
| CCDC62 | ESR2 | psi-mi:“MI:0403”(colocalization) | 0.460 |
| CCDC62 | ESR2 | psi-mi:“MI:0915”(physical association) | 0.460 |
| CCDC62 | psi-mi:“MI:0915”(physical association) | 0.400 | |
| CCDC62 | SDHA | psi-mi:“MI:0915”(physical association) | 0.400 |
| CCDC62 | PLEC | psi-mi:“MI:0915”(physical association) | 0.400 |
| CCDC62 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (5): CCDC62 (Proximity Label-MS), CCDC62 (Proximity Label-MS), CCDC62 (Affinity Capture-MS), CCDC62 (Affinity Capture-RNA), STIM1 (Cross-Linking-MS (XL-MS))
ESM2 similar proteins: A0A1W2P884, A0P8Z5, A2AM05, A2BGP7, A7E3D8, A8MT70, B0CM36, B1WC58, E9PVD1, O75410, O95447, Q1RMS0, Q2M243, Q3UPP8, Q3V036, Q4KMA0, Q4R3Q7, Q4R3X1, Q5PQS2, Q5R9L2, Q5U465, Q5U5Q9, Q5VVM6, Q5VX52, Q5XI03, Q66KC9, Q6NRH3, Q6NZK5, Q6P9F0, Q6PJW8, Q6Y685, Q70YC5, Q7Z4H7, Q86T90, Q86Z20, Q8BFU3, Q8BG89, Q8BVF4, Q8CDM4, Q8IW35
Diamond homologs: E9PVD1, Q6P9F0
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
116 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 94 |
| Likely benign | 6 |
| Benign | 3 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 1345024 | NM_201435.5(CCDC62):c.442C>T (p.Gln148Ter) | Pathogenic |
SpliceAI
2389 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:122774703:CCAGG:C | donor_loss | 1.0000 |
| 12:122777460:ATTTT:A | acceptor_gain | 1.0000 |
| 12:122777464:T:TA | acceptor_gain | 1.0000 |
| 12:122777483:A:AG | acceptor_gain | 1.0000 |
| 12:122777483:AT:A | acceptor_gain | 1.0000 |
| 12:122777484:T:G | acceptor_gain | 1.0000 |
| 12:122777484:T:TA | acceptor_gain | 1.0000 |
| 12:122777486:TTTAG:T | acceptor_loss | 1.0000 |
| 12:122777487:TTAGA:T | acceptor_loss | 1.0000 |
| 12:122777488:TA:T | acceptor_loss | 1.0000 |
| 12:122777489:A:AG | acceptor_gain | 1.0000 |
| 12:122777489:AGAAC:A | acceptor_loss | 1.0000 |
| 12:122777490:G:GA | acceptor_gain | 1.0000 |
| 12:122777490:GA:G | acceptor_gain | 1.0000 |
| 12:122777490:GAA:G | acceptor_gain | 1.0000 |
| 12:122777490:GAAC:G | acceptor_gain | 1.0000 |
| 12:122777490:GAACA:G | acceptor_gain | 1.0000 |
| 12:122777659:G:GT | donor_gain | 1.0000 |
| 12:122777679:AGAAG:A | donor_loss | 1.0000 |
| 12:122777680:GAAGG:G | donor_loss | 1.0000 |
| 12:122777681:AAGGT:A | donor_loss | 1.0000 |
| 12:122777685:T:A | donor_loss | 1.0000 |
| 12:122785715:GTA:G | acceptor_loss | 1.0000 |
| 12:122785717:A:AC | acceptor_loss | 1.0000 |
| 12:122785718:GGCTA:G | acceptor_gain | 1.0000 |
| 12:122788926:AAAGG:A | donor_loss | 1.0000 |
| 12:122788927:AAGGT:A | donor_loss | 1.0000 |
| 12:122788928:AG:A | donor_gain | 1.0000 |
| 12:122788928:AGGTA:A | donor_loss | 1.0000 |
| 12:122788929:GG:G | donor_gain | 1.0000 |
AlphaMissense
4557 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 12:122777573:G:C | R40P | 0.999 |
| 12:122777585:T:C | L44P | 0.999 |
| 12:122785777:T:C | L152P | 0.999 |
| 12:122785798:T:C | L159P | 0.999 |
| 12:122788776:G:C | A173P | 0.999 |
| 12:122777534:G:C | R27P | 0.998 |
| 12:122777543:T:C | L30P | 0.998 |
| 12:122777639:G:C | R62P | 0.998 |
| 12:122785786:G:C | R155P | 0.998 |
| 12:122785820:G:C | K166N | 0.998 |
| 12:122785820:G:T | K166N | 0.998 |
| 12:122792077:T:C | L243P | 0.998 |
| 12:122777552:T:C | L33P | 0.997 |
| 12:122777564:T:C | L37S | 0.997 |
| 12:122777626:T:A | W58R | 0.997 |
| 12:122777626:T:C | W58R | 0.997 |
| 12:122777666:G:C | R71P | 0.997 |
| 12:122781170:T:C | L79P | 0.997 |
| 12:122781275:T:C | L114P | 0.997 |
| 12:122785756:T:C | L145P | 0.997 |
| 12:122785794:G:C | A158P | 0.997 |
| 12:122785816:T:C | L165P | 0.997 |
| 12:122788839:G:C | A194P | 0.997 |
| 12:122792026:T:C | L226P | 0.997 |
| 12:122797388:T:C | L285P | 0.997 |
| 12:122777618:T:C | L55P | 0.996 |
| 12:122777628:G:C | W58C | 0.996 |
| 12:122777628:G:T | W58C | 0.996 |
| 12:122777657:T:C | L68P | 0.996 |
| 12:122781200:T:C | L89P | 0.996 |
dbSNP variants (sampled 300 via entrez): RS1000017450 (12:122793303 A>G,T), RS1000035780 (12:122790401 A>C), RS1000111074 (12:122800565 A>C,T), RS1000194091 (12:122787089 G>A,T), RS1000354213 (12:122826921 T>C), RS1000432704 (12:122774158 G>A), RS1000478962 (12:122795968 G>A), RS1000703404 (12:122791694 C>T), RS1000768063 (12:122795753 G>C), RS1000772849 (12:122803838 C>T), RS1000894826 (12:122827244 A>T), RS1000975137 (12:122821432 T>C), RS1000998558 (12:122772627 C>T), RS1001059774 (12:122814794 C>T), RS1001068798 (12:122805806 G>A)
Disease associations
OMIM: gene MIM:613481 | disease phenotypes: MIM:619803
GenCC curated gene-disease
Mondo (1): spermatogenic failure 67 (MONDO:0030718)
Orphanet (0):
HPO phenotypes
4 total (4 of 4 shown, HPO-id order):
| HPO | Term |
|---|---|
| HP:0000007 | Autosomal recessive inheritance |
| HP:0003251 | Male infertility |
| HP:0011462 | Young adult onset |
| HP:0012205 | Globozoospermia |
GWAS associations
27 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000959_10 | Parkinson’s disease | 3.000000e-13 |
| GCST002544_26 | Parkinson’s disease | 6.000000e-12 |
| GCST003984_14 | Parkinson’s disease | 3.000000e-10 |
| GCST007277_17 | Tourette syndrome | 2.000000e-06 |
| GCST010991_41 | Parkinson’s disease | 2.000000e-10 |
| GCST90000025_1005 | Appendicular lean mass | 5.000000e-14 |
| GCST90020024_427 | A body shape index | 7.000000e-14 |
| GCST90020024_429 | A body shape index | 4.000000e-09 |
| GCST90020024_431 | A body shape index | 7.000000e-14 |
| GCST90020025_34 | Waist-to-hip ratio adjusted for BMI | 2.000000e-12 |
| GCST90020025_38 | Waist-to-hip ratio adjusted for BMI | 4.000000e-19 |
| GCST90020025_39 | Waist-to-hip ratio adjusted for BMI | 3.000000e-08 |
| GCST90020025_40 | Waist-to-hip ratio adjusted for BMI | 4.000000e-08 |
| GCST90020025_43 | Waist-to-hip ratio adjusted for BMI | 1.000000e-13 |
| GCST90020025_44 | Waist-to-hip ratio adjusted for BMI | 6.000000e-13 |
| GCST90020027_1211 | Waist-hip index | 2.000000e-12 |
| GCST90020027_1240 | Waist-hip index | 2.000000e-18 |
| GCST90020027_1241 | Waist-hip index | 2.000000e-08 |
| GCST90020027_1242 | Waist-hip index | 2.000000e-08 |
| GCST90020027_1245 | Waist-hip index | 2.000000e-13 |
| GCST90020027_1246 | Waist-hip index | 7.000000e-12 |
| GCST90020027_1248 | Waist-hip index | 8.000000e-19 |
| GCST90020028_1252 | Hip circumference adjusted for BMI | 2.000000e-14 |
| GCST90020029_353 | Waist circumference adjusted for body mass index | 3.000000e-10 |
| GCST90020029_354 | Waist circumference adjusted for body mass index | 4.000000e-08 |
| GCST90020029_355 | Waist circumference adjusted for body mass index | 2.000000e-08 |
| GCST90020029_357 | Waist circumference adjusted for body mass index | 3.000000e-09 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004980 | appendicular lean mass |
| EFO:0007789 | BMI-adjusted waist circumference |
| EFO:0007788 | BMI-adjusted waist-hip ratio |
| EFO:0008039 | BMI-adjusted hip circumference |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
12 total (human), top 12 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| aristolochic acid I | increases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | increases expression | 1 |
| potassium chromate(VI) | affects cotreatment, increases expression | 1 |
| epigallocatechin gallate | affects cotreatment, increases expression | 1 |
| jinfukang | affects cotreatment, decreases expression | 1 |
| theaflavin-3,3’-digallate | affects expression | 1 |
| Benzo(a)pyrene | affects methylation, decreases methylation | 1 |
| Cisplatin | affects cotreatment, decreases expression | 1 |
| Fenfluramine | increases expression | 1 |
| Quercetin | increases expression | 1 |
| Silicon Dioxide | decreases expression | 1 |
| Acrylamide | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): spermatogenic failure 67